The Anti-Migraine Market 2007-2022
Visiongain
November 13, 2007 76 Pages - SKU: VSG1655771
|
|
Migraine is a serious neurological disorder characterised by recurrent headaches, varying in severity and frequency. Accounting for the loss of over 100 million working days in the US alone, the economic cost and social impact of migraine is significant. Furthermore, the people most susceptible to migraine are those within their most productive years (22-55), causing both personal and professional disruptions and a significant burden on healthcare services.
This in-depth management report examines the prospects for anti-migraine drugs from 2007, right through till 2022. It delivers sales forecasts for the leading pharmaceutical products, so that you can analyse your pipeline and market. The market for anti-migraine drugs is the slowest growing segments in the pain management market with a CAGR of 0.11% for the period 2006-2012. However this slow growth will be due to the 2009 patent expiry of the leading product in the market.
Nevertheless, visiongain predicts that with a high prevalence of migraine, the success of newer triptans and the launch of new therapies, the market will expand further beyond 2012, generating revenues of $5268m in 2022, increasing CAGR for the period 2006-2022 to 2.7%. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints.
The Anti-Migraine Market 2007 examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.
In particular, The Anti-Migraine Market concentrates on the following essential aspects of the market:
- Discussion of the current pharmaceutical market
- Forecast of the worldwide pharmaceutical market from 2007-2022
- Drivers and restraints facing the anti-migraine market
- Opportunities and threats facing the anti-migraine market
- Growth of the anti-migraine sector between 2007-2022
- Commercial prospects for the market-leading drugs, with sales forecasts from 2007-2012
- The potential of generics manufacturers to penetrate this market
- Pipeline developments with blockbuster potential
- Currently marketed drugs with blockbuster potential
- Discussion of unmet therapeutic needs and relative advantages of products
Why you should buy this report:
- To receive a comprehensive analysis of the prospects for anti-migraine drugs from 2007-2012
- To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2007-2012
- To determine key activities of leading companies
- To discover “hot” pipeline developments and up-and-coming products
- To determine the forces that influence the market for anti-migraine products:
- Competitive characteristics of the market
- Drivers
- Restraints
- Strengths, weaknesses, opportunities and threats (SWOT analysis)
- To find out where the anti-migraine market is heading - both technologically and commercially
The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC drugs. The report also focuses on the technological issues, including the latest trends, patents, new products and other influential factors. The study also assesses the challenges faced by companies in the pain industry, and what exciting market opportunities exist in this up- and-coming therapeutic area.
Why You Must Buy This Report?
This report features news, insights, the latest developments and an in depth survey of the pain market with up-to-date analysis as well as tables, graphs and charts. This report is a vital addition to gaining an understanding of this market sector and will give your company 'the edge' on your competitors. You can not afford to be without this latest report from visiongain.
Unique benefits to you when you order this report
- You can access your report whichever country you are in without using harddrive space
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
|
Additional Information- Companies Mentioned in this Report
- Abbott Laboratories
- Addex
- Alexza
- Almirall Prodesfarma
- Apothecon
- AstraZeneca
- Bayer
- Bedford
- Bristol-Myers Squibb
- CeNeS
- Dr. Reddy’s
- Elan
- Faust Pharmaceuticals
- FDA
- GD Searle
- Geneva Pharmaceuticals
- GSK
- Harvest Pharms
- Houston University
- J&J
- Lilly
- Menarini
- Merck & Co
- MHRA
- Novartis
- Odyssey Pharms
- Ortho-McNeil
- Pfizer
- Pharmacia
- Pozen
- Reckitt Benckiser
- Roche
- Roxro
- Sanofi
- UCB
- Vernalis
- Winston Laboratories
- Wyeth
- Chapter 1 Executive Summary
- Chapter 2 Introduction
- 2.1 What are Migraines
- 2.1.1 What Causes Migraine?
- 2.1.2 Symptom Phases of Migraine
- 2.1.2.1 Prodrome Phase
- 2.1.2.2 Auras Phase
- 2.1.2.3 Attack Phase
- 2.1.2.4 Postdrome Phase
- 2.2 What is Headache Pain?
- 2.2.1 Tension Headaches
- 2.2.2 Cluster Headaches
- 2.3 Which Drugs are Approved for Migraine Treatment?
- 2.3.1 Acute Symptomatic Relief of Migraine Pain
- 2.3.1.1 What are the Triptans?
- 2.3.1.1.1 Sumatriptan (Imitrex, Imigran, Imigran Recovery)
- 2.3.1.1.2 Rizatriptan (Maxalt)
- 2.3.1.1.3 Zolmitriptan (Zomig)
- 2.3.1.1.4 Eletriptan (Relpax)
- 2.3.1.1.5 Naratriptan (Naramig)
- 2.3.1.1.6 Almotriptan (Axert, Almogran)
- 2.3.1.1.7 Frovatriptan (Frova)
- 2.3.1.2 Which Ergots have the FDA Approved for Migraine Treatment?
- 2.3.1.2.1 Side Effects of Ergots
- 2.3.1.2.2 Withdrawal of Drug
- 2.3.1.3 Which Analgesics Have the FDA Approved for Migraine Treatment?
- 2.3.1.4 Which Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Have Been Approved by the FDA?
- 2.4 Opioids on the Market
- 2.5 Beta Blockers on the Market
- 2.6 Anticonvulsants for Migraine (Depakote and Topamax)
- 2.7 Antidepressants
- 2.8 Calcium-Channel Blockers
- 2.9 Other Drug Classes Under Investigation
- Chapter 3 The Global Anti-Migraine Market
- 3.1 The Global Anti-Migraine Market Analysis
- 3.1.1 GSK's Blockbuster Migraine Drug Imitrex Faces Loss of Sales
- 3.1.1.1 GSK Waiting Approval for New Potential Anti-Migraine Blockbuster Drug
- 3.1.2 AstraZeneca's Zomig - The New Market Leader Perhaps?
- 3.1.3 Relpax Shows Positive Growth
- 3.1.4 What Does the Future Hold for Migraine Therapy?
- 3.1.5 What are the Unmet Needs in the Management of Migraine?
- 3.1.6 Visiongain Believes That Significant Advances Will Occur in this Market with Potentially High Revenues for Next-Generation Products
- 3.1.7 GSK Currently Leads the Anti-Migraine Market
- 3.1.8 Imitrex will be Overtaken by Zomig as the Leading Anti-Migraine Product
- 3.1.9 The Top Ten Countries in the Anti-Migraine Market
- Chapter 4 Forces Affecting the Anti-Migraine Market
- 4.1 SWOT Analysis of the Anti-Migraine Market
- 4.1.1 Market Drivers
- 4.1.2 Market Restraints
- 4.1.3 Why Growth in the Market is Expected?
- 4.2 Success of the Triptan Drugs
- 4.2.1 Niche Markets and the Success of the Triptan
- 4.2.2 What are the Therapeutic Advantages Offered by the Newer Triptans?
- 4.2.3 Will a Single Triptan Reign Supreme?
- 4.3 Lack of Adequate Reimbursement Limits Potential of Anti-Migraine Drugs
- 4.4 Choosing the Right Medication
- 4.5 Patient Problems with Anti-Migraine drugs
- 4.6 What are the Costs of Migraine to the US?
- 4.6.1 Cost of Migraine
- 4.6.2 How much Does Migraine Cost the US in Terms of Medical, Missed Workdays and Lost Productivity?
- 4.7 FDA Reject Endo’s Attempt to Expand the Label for Frova
- 4.8 Complications of the Triptans
- Chapter 5 The Prevalence of Migraine
- 5.1 What is the Global Prevalence of Migraine?
- 5.1.1 Why Will the Prevalence of Migraine Increase?
- 5.2 Prevalence of Migraine in the US
- 5.3 What are the Affects of Migraine on Specific Populations?
- 5.3.1 Prevalence by Gender
- 5.3.1.1 Menstrual Migraine
- 5.3.1.2 Pregnancy and Migraine
- 5.3.2 Prevalence by Age
- 5.3.2.1 Migraine in Children
- 5.3.2.2 Migraine in Later Life
- Chapter 6 Pipeline Developments
- 6.1 Agents in Phase II of Clinical Development
- 6.1.1 Addex’s ADX10059
- 6.1.2 GSK’s 274150, 468816 and 705498
- 6.2 Agents in Phase III of Clinical Development
- 6.2.1 Merck’s MK0974
- 6.2.2 GSK’s 406381
- 6.3 Time is Running out for Pozen & GSK After the FDA Request More Clinical Data on Trexima
- 6.4 Pozen’s MT-100
- 6.5 Discussion of Current Pipeline Developments
- 6.6 Summary of Pipeline Products Phase II and Above
- Chapter 7 Alternative Therapies
- 7.1 Acupuncture
- 7.2 Biofeedback
- 7.3 Butterbur Root
- 7.4 Chiropractic
- 7.5 CoQ10
- 7.6 Feverfew Leaf
- 7.7 Ginkgo
- 7.8 Glucosamine
- 7.9 Hormones
- 7.9.1 Melatonin
- 7.9.2 Estriol
- 7.10 Magnesium
- 7.11 NTI Tension Suppression System
- 7.12 Vitamin B2
- Chapter 8 Conclusion
- 8.1 Migraine is a Serious Condition with High Prevalence
- 8.2 Migraine Market Analysis
- 8.2.1 The Anti-Migraine Market Will Suffer From the Patent Expiry of its Leading Product
- 8.2.2 How have Anti-Migraine Drugs Succeeded?
- 8.2.3 How an Increase in Prevalence will affect Sales Growth
- 8.2.4 Why is a Growth in the Market Expected?
- 8.2.5 Niche Markets - Menstrual Migraine
- 8.2.6 Market Drivers
- 8.2.7 Market Restraints
- 8.3 Geographical Breakdown of Revenues in the Anti-Migraine Market
- 8.3.1 Sales of Anti-Migraine Drugs Will Decrease in the US from 2007 to 2012
- 8.3.2 France Will Have the Second-Highest Sales of Anti-Migraine Drugs
- 8.4 There are Promising Developments Currently in Mid to Late Stage Clinical Testing
- 8.5 Outlook for the Future of the Anti-Migraine Market
- Appendix A: About Visiongain
- Appendix B: Visiongain Report Evaluation Form
- TABLES
- Table 2.1 FDA Approved Triptans for Migraine Treatment
- Table 2.2 FDA Approved Ergots for Migraine Treatment
- Table 2.3 FDA Approved Analgesics for Migraine Treatment
- Table 2.4 FDA Approved NSAIDs for Migraine Treatment
- Table 3.1 The World Anti-Migraine Market Forecast ($m), 2007-2022
- Table 3.2 Imitrex Forecast ($m), 2007-2012
- Table 3.3 Zomig Forecast ($m), 2007-2012
- Table 3.4 Relpax Forecast ($m), 2007-2012
- Table 3.5 Top 10 Leading Companies in the Anti-Migraine Market, Revenue and Market Share, 2006
- Table 3.6 Top Ten Countries in the Anti-Migraine Market Revenue ($m) Forecast 2007-2012
- Table 4.1 SWOT Analysis of the Anti-Migraine Market
- Table 4.2 Economic Burden of Migraine in the US
- Table 5.1 Lifetime Prevalence of Headaches among Gender
- Table 6.1 Summary of Pipeline Products Phase II and Above, 2007
- Table 8.1 Geographical Breakdown of Revenues in the Anti-Migraine Market ($m), 2006-2012
- GRAPHS
- Graph 1.1 Top Anti-Migraine Products Revenue Forecast ($m), 2007-2012
- Graph 3.1 Anti-Migraine World Market Revenue Forecast ($m), 2007-2022
- Graph 3.2 Imitrex Revenue Forecast ($m), 2007-2012
- Graph 3.3 Zomig Revenue Forecast ($m), 2007-2012
- Graph 3.4 Relpax Revenue Forecast ($m), 2007-2012
- Graph 3.5 Top 10 Leading Companies in the Anti-Migraine Market ($m), 2006
- Graph 8.1 Total Sales of Anti-Migraine Drugs ($m), 2007-2022
- Graph 8.2 Sales of the Leading Anti-Migraine Drugs ($m), 2007-2012
- CHARTS
- Chart 3.1 Leading Companies in the Anti-Migraine Market, Market Share (%), 2006
- Chart 3.2 Top Countries in the Anti-Migraine Market, Market Share (%), 2006
- Chart 3.3 Top Countries in the Anti-Migraine Market, Market Share (%), 2009
- Chart 3.4 Top Countries in the Anti-Migraine Market, Market Share (%), 2012
Share this report
Other tasks Related Markets CNS/Neurology Reports- Traumatic Brain Injury Global Clinical Trials Review, H1, 2012
- Tension -Type Headache Global Clinical Trials Review, H1, 2012
- Cluster Headache Syndrome Global Clinical Trials Review, H1, 2012
- Cerebral Infarction (Brain Infarction) Global Clinical Trials Review, H1, 2012
- Brain Ischemia Global Clinical Trials Review, H1, 2012
Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
